DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report report published on Saturday. The brokerage issued a hold rating on the stock.

Separately, HC Wainwright reissued a buy rating and set a $10.00 price objective on shares of DBV Technologies in a research note on Wednesday, February 21st.

DBV Technologies Stock Performance

DBVT stock opened at $0.71 on Friday. The stock has a market capitalization of $136.07 million, a P/E ratio of -1.81 and a beta of 0.75. DBV Technologies has a one year low of $0.65 and a one year high of $2.37. The company has a 50 day moving average price of $0.78 and a two-hundred day moving average price of $0.87.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.10. DBV Technologies had a negative net margin of 461.32% and a negative return on equity of 46.33%. The company had revenue of $8.88 million during the quarter, compared to analysts’ expectations of $1.10 million. During the same period in the previous year, the company earned ($0.23) EPS. Research analysts forecast that DBV Technologies will post -0.88 earnings per share for the current fiscal year.

Institutional Trading of DBV Technologies

A number of institutional investors have recently added to or reduced their stakes in the business. Cowen AND Company LLC acquired a new position in DBV Technologies in the 4th quarter worth $49,000. Optiver Holding B.V. lifted its holdings in DBV Technologies by 595.2% in the 3rd quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock worth $374,000 after buying an additional 235,337 shares in the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new stake in shares of DBV Technologies in the 3rd quarter valued at about $94,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.